fig1

Figure 1. Overview of CDK4/6 inhibitor treatment and liquid biopsy in ER+/HER2- metastatic breast cancer patients. CDK4/6 inhibitors prevent the phosphorylation of Rb and downstream activation of the transcriptional profile required for progression to the S-phase of the cell cycle. In the anti-CDK4/6 therapy clinical setting, a liquid biopsy may be used to direct therapy, monitor patient response over time, and detect progression. Currently, research efforts focused on monitoring genetic alterations in cfDNA through liquid biopsy have made limited progress. Epigenetic profiling of cfDNA may reveal new biomarkers of CDK4/6 inhibitor efficacy or resistance.